Axa Raises Holdings in Heron Therapeutics Inc (HRTX)

Axa grew its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 12.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,900 shares of the biotechnology company’s stock after buying an additional 3,100 shares during the quarter. Axa’s holdings in Heron Therapeutics were worth $883,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of HRTX. BlackRock Inc. lifted its holdings in shares of Heron Therapeutics by 29.4% in the 2nd quarter. BlackRock Inc. now owns 4,544,731 shares of the biotechnology company’s stock worth $176,563,000 after buying an additional 1,032,010 shares during the period. FMR LLC lifted its holdings in shares of Heron Therapeutics by 6.5% in the 2nd quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock worth $438,654,000 after buying an additional 693,699 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Heron Therapeutics in the 2nd quarter worth $15,249,000. First Light Asset Management LLC lifted its holdings in shares of Heron Therapeutics by 76.8% in the 2nd quarter. First Light Asset Management LLC now owns 836,737 shares of the biotechnology company’s stock worth $32,507,000 after buying an additional 363,462 shares during the period. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Heron Therapeutics by 396.2% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 342,400 shares of the biotechnology company’s stock worth $10,837,000 after buying an additional 273,400 shares during the period.

In related news, VP Kimberly Manhard sold 6,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $32.07, for a total transaction of $192,420.00. Following the transaction, the vice president now directly owns 6,000 shares of the company’s stock, valued at approximately $192,420. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Kevin C. Tang sold 2,695,000 shares of the company’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total value of $96,346,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,701,494 shares of company stock valued at $96,553,796 over the last 90 days. 16.20% of the stock is currently owned by company insiders.

HRTX has been the subject of a number of analyst reports. Cantor Fitzgerald set a $50.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, September 27th. BidaskClub cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. ValuEngine cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 4th. Zacks Investment Research cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. Finally, Stifel Nicolaus initiated coverage on Heron Therapeutics in a research note on Thursday, September 13th. They set a “buy” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $52.09.

Shares of NASDAQ HRTX opened at $27.88 on Friday. The firm has a market cap of $2.18 billion, a P/E ratio of 7.64 and a beta of 1.48. Heron Therapeutics Inc has a 1-year low of $15.00 and a 1-year high of $42.90.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). The company had revenue of $19.79 million for the quarter, compared to analysts’ expectations of $19.84 million. Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The company’s revenue for the quarter was up 130.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.77) earnings per share. As a group, analysts anticipate that Heron Therapeutics Inc will post -2.34 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.wkrb13.com/2018/12/07/axa-raises-holdings-in-heron-therapeutics-inc-hrtx.html.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Read More: Is a Roth IRA right for you?

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply